GLPG
Lakefront Biotherapeutics NV
Price Chart
Latest Quote
$27.73
Current Price| Open | $28.53 |
| Day High | $28.53 |
| Day Low | $27.16 |
| Volume | 286,745 |
Stock Information
Note: Financial values converted from EUR to USD
| Shares Outstanding | 65.90M |
| Total Debt | $7.32M |
| Cash Equivalents | $3.39B |
| Revenue | $1.19B |
| Net Income | $554.78M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.86B |
| P/E Ratio | 3.18 |
| EPS (TTM) | $8.71 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-1.09B |
| Sales | $1.19B |
| Income | $554.78M |
| Book/sh | $2.90 |
| Cash/sh | $45.26 |
Financial Ratios
| Quick Ratio | 30.23 |
| Current Ratio | 30.48 |
| Debt/Eq | 0.20 |
Returns & Margins
| ROA | 10.66% |
| ROE | 16.26% |
| Gross Margin | 53.99% |
| Operating Margin | -982.92% |
| Profit Margin | 46.83% |
Ownership
| Insider Ownership | 25.35% |
| Institutional Ownership | 22.31% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -20.32 |
| P/S | 1.78 |
| P/B | 9.57 |
Analyst Data
| Recommendation | none |
| Target Price | $27.09 |
Technical Indicators
| SMA20 | $28.09 |
| SMA50 | $28.18 |
| SMA200 | $31.50 |
| RSI | 49.42 |
| ATR | 0.6604 |
| Shares Float | 44.52M |
| Short Float | 3.39% |
| Short Ratio | 6.95 |
| Rel Volume | 0.84 |
Performance History
| Week | -2.21% |
| Month | +6.35% |
| Quarter | -13.00% |
| 6 Months | -8.94% |
| YTD | -14.16% |
| Year | +1.36% |
| 3 Years | -32.75% |
| 5 Years | -64.33% |
| 10 Years | -44.64% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $28.30 | 159,488 |
| 2026-06-17 | $28.37 | 125,293 |
| 2026-06-16 | $28.18 | 199,975 |
| 2026-06-15 | $28.66 | 383,468 |
| 2026-06-12 | $28.90 | 91,349 |
| 2026-06-11 | $28.94 | 161,242 |
| 2026-06-10 | $28.61 | 291,518 |
| 2026-06-09 | $28.27 | 192,522 |
| 2026-06-08 | $27.83 | 214,730 |
| 2026-06-05 | $28.02 | 138,611 |
| 2026-06-04 | $28.11 | 148,929 |
| 2026-06-03 | $27.51 | 404,664 |
| 2026-06-02 | $27.27 | 303,524 |
| 2026-06-01 | $27.54 | 214,498 |
| 2026-05-29 | $28.35 | 117,841 |
| 2026-05-28 | $28.32 | 93,242 |
| 2026-05-27 | $27.73 | 156,226 |
| 2026-05-26 | $27.67 | 69,614 |
About Lakefront Biotherapeutics NV
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
đ° Latest News
Lakefront Biotherapeutics NV (AMS:LKFT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Simply Wall St. âĸ 2026-05-10T06:01:08Z
Galapagos Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-07T20:58:37Z
RBC Cuts Galapagos NV (GLPG) Price Target to $28, Maintains Sector Perform Ahead of Q1
Insider Monkey âĸ 2026-04-24T13:43:58Z
Galapagos NV (GLPG) Signs Agreement with Gilead on Ouro Medicines Assets
Insider Monkey âĸ 2026-04-04T12:16:40Z
Galapagos Partners With Gilead on Gamgertamig, Unlocks $500M Cash and Eyes 2027 Registrational Trials
MarketBeat âĸ 2026-03-31T13:26:19Z
Gilead Expands Autoimmune Ambitions With Ouro Deal And Galapagos Collaboration
Simply Wall St. âĸ 2026-03-31T08:16:30Z
Gilead to Acquire Ouro Medicines in $2.18B Deal, Expand Inflammation Pipeline
Insider Monkey âĸ 2026-03-27T00:55:02Z
Sector Update: Health Care Stocks Advance Late Afternoon
MT Newswires âĸ 2026-03-24T19:50:27ZGilead Strengthens Inflammation Portfolio With Ouro Medicines Deal
Zacks âĸ 2026-03-24T19:03:00Z
Gilead Sciences to Acquire Ouro Medicines in Up to $2.18 Billion Deal
MT Newswires âĸ 2026-03-24T10:40:43Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $34,701,832 | $2,959,505 | $0 | $0 |
| Cost Of Revenue | $34,701,832 | $40,685,027 | $0 | $0 |
| Total Revenue | $1,297,990,413 | $321,681,639 | $279,757,261 | $281,536,932 |
| Operating Revenue | $1,297,990,413 | $321,681,639 | $279,757,261 | $281,536,932 |
| Expenses | ||||
| Interest Expense | $2,587,233 | $1,063,135 | $2,065,585 | $10,683,860 |
| Total Expenses | $712,868,470 | $541,471,576 | $382,759,943 | $434,480,097 |
| Other Income Expense | $-286,740,573 | $111,792,506 | $18,966,040 | $60,099,194 |
| Net Non Operating Interest Income Expense | $52,734,274 | $104,397,244 | $90,601,002 | $10,163,379 |
| Total Other Finance Cost | $-1,244,019 | $-695,530 | $235,733 | $268,409 |
| Interest Expense Non Operating | $2,587,233 | $1,063,135 | $2,065,585 | $10,683,860 |
| Operating Expense | $678,166,638 | $500,786,549 | $382,759,943 | $434,480,097 |
| Other Operating Expenses | $296,417 | $-19,123,585 | $-27,599,486 | $-10,956,938 |
| Selling And Marketing Expense | $1,624,460 | $3,282,763 | $2,072,587 | $1,478,586 |
| General And Administrative Expense | $129,032,557 | $109,775,935 | $107,919,242 | $119,083,905 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $372,846,301 | $-1,496,091 | $-4,653,985 | $-83,348,114 |
| Net Interest Income | $52,734,274 | $104,397,244 | $90,601,002 | $10,163,379 |
| Interest Income | $54,077,488 | $104,764,849 | $92,902,321 | $21,115,649 |
| Normalized Income | $599,371,354 | $-89,812,171 | $-19,637,157 | $-130,826,477 |
| Net Income From Continuing And Discontinued Operation | $374,470,762 | $86,453,494 | $247,049,827 | $-254,394,908 |
| Total Operating Income As Reported | $344,309,716 | $-219,789,937 | $-103,002,683 | $-152,941,998 |
| Net Income Common Stockholders | $374,470,762 | $86,453,494 | $247,049,827 | $-254,394,908 |
| Net Income | $374,470,762 | $86,453,494 | $247,049,827 | $-254,394,908 |
| Net Income Including Noncontrolling Interests | $374,470,762 | $86,453,494 | $247,049,827 | $-254,394,908 |
| Net Income Discontinuous Operations | $1,624,460 | $87,949,585 | $251,703,813 | $-171,046,794 |
| Net Income Continuous Operations | $372,846,301 | $-1,496,091 | $-4,653,985 | $-83,348,114 |
| Pretax Income | $351,115,645 | $-3,600,187 | $6,564,360 | $-82,680,592 |
| Special Income Charges | $-240,812,227 | - | - | - |
| Interest Income Non Operating | $54,077,488 | $104,764,849 | $92,902,321 | $21,115,649 |
| Operating Income | $585,121,943 | $-219,789,937 | $-103,002,683 | $-152,943,165 |
| Depreciation Amortization Depletion Income Statement | $11,070,136 | $15,371,688 | $18,778,154 | $10,022,173 |
| Depreciation And Amortization In Income Statement | $11,070,136 | $15,371,688 | $18,778,154 | $10,022,173 |
| Depreciation Income Statement | $11,070,136 | $15,371,688 | $18,778,154 | $10,022,173 |
| Gross Profit | $1,263,288,581 | $280,996,612 | $279,757,261 | $281,536,932 |
| Per Share | ||||
| Diluted EPS | $5.68 | $1.31 | $3.75 | $-3.87 |
| Basic EPS | $5.68 | $1.31 | $3.75 | $-3.87 |
| Other | ||||
| Tax Effect Of Unusual Items | $-60,215,520 | $23,476,426 | $3,982,868 | $12,620,831 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $705,649,424 | $-61,232,348 | $40,594,001 | $-55,580,580 |
| Total Unusual Items | $-286,740,573 | $111,792,506 | $18,966,040 | $60,099,194 |
| Total Unusual Items Excluding Goodwill | $-286,740,573 | $111,792,506 | $18,966,040 | $60,099,194 |
| Reconciled Depreciation | $65,205,974 | $53,097,210 | $50,930,096 | $76,515,345 |
| EBITDA (Bullshit earnings) | $418,908,852 | $50,560,158 | $59,560,041 | $4,518,614 |
| EBIT | $353,702,878 | $-2,537,052 | $8,629,945 | $-71,996,731 |
| Diluted Average Shares | $76,901,621 | $77,190,620 | $76,886,450 | $76,624,973 |
| Basic Average Shares | $76,901,621 | $77,190,620 | $76,886,450 | $76,624,973 |
| Diluted NI Availto Com Stockholders | $374,470,762 | $86,453,494 | $247,049,827 | $-254,394,908 |
| Tax Provision | $-21,730,657 | $-2,104,096 | $11,218,345 | $667,522 |
| Impairment Of Capital Assets | $266,206,088 | - | - | - |
| Restructuring And Mergern Acquisition | $-25,393,861 | - | - | - |
| Gain On Sale Of Security | $-45,928,346 | $111,792,506 | $18,966,040 | $60,099,194 |
| Research And Development | $536,143,067 | $391,479,747 | $281,589,447 | $314,852,371 |
| Selling General And Administration | $130,657,018 | $113,058,698 | $109,991,830 | $120,562,491 |
| Other Gand A | $34,516,279 | $40,686,194 | $27,285,564 | $27,790,874 |
| Salaries And Wages | $94,516,278 | $69,089,741 | $80,633,678 | $91,293,032 |
Fetched: 2026-04-30
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $3,775,259,605 | $3,106,625,001 | $3,031,979,186 | $2,695,600,383 |
| Total Assets | $3,975,397,308 | $4,826,372,907 | $5,085,069,367 | $5,524,974,834 |
| Total Non Current Assets | $381,679,304 | $929,243,773 | $578,605,430 | $580,582,324 |
| Other Non Current Assets | $3,454,312 | $3,793,908 | $6,828,101 | $6,742,910 |
| Non Current Prepaid Assets | $0 | $6,368,304 | $11,925,545 | $0 |
| Non Current Deferred Assets | $227,564 | $1,720,154 | $1,314,039 | $1,590,617 |
| Non Current Deferred Taxes Assets | $227,564 | $1,720,154 | $1,314,039 | $1,590,617 |
| Non Current Note Receivables | $24,711,168 | $0 | - | - |
| Non Current Accounts Receivable | $203,538,333 | $204,450,925 | $164,840,703 | $139,970,823 |
| Investmentin Financial Assets | $0 | $233,611,854 | $0 | $0 |
| Goodwill And Other Intangible Assets | $989,614 | $274,094,990 | $230,438,788 | $252,265,138 |
| Other Intangible Assets | $989,614 | $192,393,509 | $149,265,957 | $170,793,556 |
| Current Assets | $3,593,718,004 | $3,897,129,133 | $4,506,463,937 | $4,944,392,511 |
| Assets Held For Sale Current | $0 | $12,971,175 | $25,773,135 | $0 |
| Current Deferred Assets | $6,546,855 | $35,259,656 | $17,075,504 | $14,037,811 |
| Restricted Cash | $0 | $48,037,110 | $0 | - |
| Prepaid Assets | $120,201 | $120,201 | $861,244 | $569,495 |
| Inventory | $26,249,270 | $59,740,926 | $86,332,126 | $61,763,332 |
| Receivables | $62,087,757 | $102,800,792 | $76,619,208 | $90,260,239 |
| Other Receivables | $50,921,927 | $64,907,223 | $56,203,757 | $57,357,917 |
| Accounts Receivable | $11,165,830 | $37,893,569 | $20,415,451 | $32,902,322 |
| Cash Cash Equivalents And Short Term Investments | $3,498,713,921 | $3,638,199,274 | $4,299,802,719 | $4,777,759,300 |
| Cash And Cash Equivalents | $102,541,719 | $74,966,740 | $194,658,651 | $592,971,167 |
| Cash Financial | $102,541,719 | $74,966,740 | $83,793,907 | $534,621,302 |
| Cash Equivalents | - | $0 | $110,864,744 | $58,349,865 |
| Financial Assets Designatedas Fair Value Through Profitor Loss Total | - | - | $15,841,988 | $0 |
| Other Current Assets | - | - | - | $2,334 |
| Debt | ||||
| Total Debt | $8,069,786 | $13,679,542 | $11,198,506 | $25,558,408 |
| Long Term Debt And Capital Lease Obligation | $6,052,048 | $9,619,559 | $5,769,635 | $17,145,524 |
| Current Debt And Capital Lease Obligation | $2,017,738 | $4,059,984 | $5,428,871 | $8,412,884 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $199,148,089 | $1,445,652,915 | $1,822,651,393 | $2,577,109,313 |
| Total Non Current Liabilities Net Minority Interest | $20,757,381 | $1,054,614,293 | $1,322,916,308 | $1,967,308,877 |
| Other Non Current Liabilities | $14,705,333 | $39,469,016 | $36,842,105 | $25,449,877 |
| Non Current Deferred Liabilities | $0 | $1,003,076,191 | $1,277,628,644 | $1,918,248,311 |
| Non Current Deferred Taxes Liabilities | $0 | $24,110,164 | $27,549,305 | $23,512,662 |
| Current Liabilities | $178,390,708 | $391,038,622 | $499,735,085 | $609,800,435 |
| Other Current Liabilities | $45,396,195 | $39,158,594 | $37,395,261 | $9,925,312 |
| Current Deferred Liabilities | $37,344 | $271,298,864 | $299,066,398 | $426,690,390 |
| Payables And Accrued Expenses | $39,207,608 | $76,521,180 | $157,844,554 | $164,771,850 |
| Payables | $39,184,268 | $75,246,819 | $157,205,039 | $164,012,135 |
| Total Tax Payable | $1,115,649 | $290,582 | $65,352 | $1,192,671 |
| Accounts Payable | $38,068,619 | $74,956,237 | $157,139,687 | $155,558,406 |
| Other Payable | - | - | - | $7,261,057 |
| Equity | ||||
| Common Stock Equity | $3,776,249,219 | $3,380,719,991 | $3,262,417,974 | $2,947,865,522 |
| Total Equity Gross Minority Interest | $3,776,249,219 | $3,380,719,991 | $3,262,417,974 | $2,947,865,522 |
| Stockholders Equity | $3,776,249,219 | $3,380,719,991 | $3,262,417,974 | $2,947,865,522 |
| Gains Losses Not Affecting Retained Earnings | $-6,581,865 | $366,437 | $-8,275,178 | $-7,522,465 |
| Other Equity Adjustments | $-10,079,356 | $-3,685,377 | $-6,873,614 | $-5,663,438 |
| Retained Earnings | $245,742,790 | $-156,734,739 | $-266,395,142 | $-579,634,722 |
| Long Term Equity Investment | $54,625,977 | $61,782,004 | $15,841,988 | - |
| Other | ||||
| Ordinary Shares Number | $76,901,704 | $76,901,704 | $76,901,704 | $76,829,864 |
| Share Issued | $76,901,704 | $76,901,704 | $76,901,704 | $76,829,864 |
| Tangible Book Value | $3,775,259,605 | $3,106,625,001 | $3,031,979,186 | $2,695,600,383 |
| Invested Capital | $3,776,249,219 | $3,380,719,991 | $3,262,417,974 | $2,947,865,522 |
| Working Capital | $3,415,327,296 | $3,506,090,511 | $4,006,728,852 | $4,334,592,075 |
| Capital Lease Obligations | $8,069,786 | $13,679,542 | $11,198,506 | $25,558,408 |
| Total Capitalization | $3,776,249,219 | $3,380,719,991 | $3,262,417,974 | $2,947,865,522 |
| Foreign Currency Translation Adjustments | $3,497,491 | $4,051,815 | $-1,401,564 | $-1,859,027 |
| Additional Paid In Capital | $3,194,064,608 | $3,194,064,608 | $3,194,064,608 | $3,192,387,633 |
| Capital Stock | $343,023,685 | $343,023,685 | $343,023,685 | $342,635,075 |
| Common Stock | $343,023,685 | $343,023,685 | $343,023,685 | $342,635,075 |
| Employee Benefits | $0 | $2,449,527 | $2,675,925 | $6,465,165 |
| Non Current Pension And Other Postretirement Benefit Plans | $0 | $2,449,527 | $2,675,925 | $6,465,165 |
| Non Current Deferred Revenue | $0 | $978,966,027 | $1,250,079,339 | $1,894,735,649 |
| Long Term Capital Lease Obligation | $6,052,048 | $9,619,559 | $5,769,635 | $17,145,524 |
| Current Deferred Revenue | $37,344 | $271,298,864 | $299,066,398 | $426,690,390 |
| Current Capital Lease Obligation | $2,017,738 | $4,059,984 | $5,428,871 | $8,412,884 |
| Pensionand Other Post Retirement Benefit Plans Current | $38,634,613 | $0 | - | - |
| Current Provisions | $53,097,210 | - | - | - |
| Current Accrued Expenses | $23,340 | $1,274,361 | $639,515 | $759,715 |
| Investments And Advances | $54,625,977 | $295,393,858 | $15,841,988 | $0 |
| Goodwill | $0 | $81,701,481 | $81,172,831 | $81,471,583 |
| Net PPE | $94,132,336 | $143,421,634 | $147,416,266 | $180,012,835 |
| Accumulated Depreciation | $-69,575,212 | $-61,911,541 | $-59,822,616 | $-71,315,205 |
| Gross PPE | $163,707,548 | $205,333,175 | $207,238,882 | $251,328,040 |
| Leases | $16,564,360 | $28,690,629 | $27,043,995 | $40,651,184 |
| Other Properties | $3,711,051 | $10,042,012 | $17,123,351 | $28,625,277 |
| Machinery Furniture Equipment | $44,250,204 | $66,222,429 | $57,219,045 | $78,516,745 |
| Land And Improvements | $99,181,934 | $100,378,106 | $105,852,490 | $103,534,833 |
| Properties | $0 | $0 | $0 | $0 |
| Raw Materials | $26,249,270 | $59,740,926 | $64,491,772 | $45,595,752 |
| Other Short Term Investments | $3,396,172,203 | $3,563,232,534 | $4,105,144,068 | $4,184,788,133 |
| Finished Goods | - | $0 | $7,138,522 | $9,409,499 |
| Work In Process | - | $0 | $14,701,832 | $6,758,081 |
Fetched: 2026-04-30
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-316,623,872 | $-469,291,626 | $-496,257,433 | $-627,250,546 |
| Operating Activities | ||||
| Operating Cash Flow | $-300,450,457 | $-373,469,478 | $-473,765,894 | $-584,133,497 |
| Cash Flow From Continuing Operating Activities | $-300,450,457 | $-373,469,478 | $-473,767,061 | $-584,133,497 |
| Operating Gains Losses | $20,633,679 | $-89,087,407 | $21,951,219 | $-49,064,067 |
| Investing Activities | ||||
| Capital Expenditure | $-16,173,416 | $-95,822,148 | $-22,491,539 | $-43,117,049 |
| Investing Cash Flow | $337,045,158 | $257,436,103 | $83,073,870 | $-1,453,511,475 |
| Cash Flow From Continuing Investing Activities | $337,045,158 | $257,436,103 | $83,073,870 | $-1,453,511,475 |
| Net Other Investing Changes | $-23,339,946 | - | - | $-11,669,973 |
| Financing Activities | ||||
| Financing Cash Flow | $-3,819,582 | $-5,746,295 | $-5,836,153 | $-1,735,325 |
| Cash Flow From Continuing Financing Activities | $-3,819,582 | $-5,746,295 | $-5,836,153 | $-1,735,325 |
| Net Other Financing Charges | - | - | $2,065,585 | $7,813,047 |
| Issuance Of Capital Stock | - | - | - | - |
| Net Common Stock Issuance | - | - | - | - |
| Common Stock Issuance | - | - | - | - |
| Other | ||||
| Repayment Of Debt | $-3,819,582 | $-5,746,295 | $-7,901,739 | $-9,548,372 |
| End Cash Position | $102,541,719 | $74,966,740 | $194,666,820 | $592,971,167 |
| Beginning Cash Position | $74,966,740 | $194,666,820 | $592,971,167 | $2,606,334,426 |
| Effect Of Exchange Rate Changes | $-5,200,140 | $2,079,589 | $-1,776,170 | $26,015,871 |
| Changes In Cash | $32,775,119 | $-121,779,669 | $-396,528,178 | $-2,039,379,130 |
| Net Issuance Payments Of Debt | $-3,819,582 | $-5,746,295 | $-7,901,739 | $-9,548,372 |
| Net Long Term Debt Issuance | $-3,819,582 | $-5,746,295 | $-7,901,739 | $-9,548,372 |
| Long Term Debt Payments | $-3,819,582 | $-5,746,295 | $-7,901,739 | $-9,548,372 |
| Interest Received Cfi | $70,542,653 | $34,424,086 | $17,230,715 | $3,496,324 |
| Net Investment Purchase And Sale | $282,800,790 | $329,274,123 | $93,672,539 | $-1,268,563,409 |
| Sale Of Investment | $4,326,511,786 | $4,281,060,742 | $4,066,298,229 | $1,915,745,102 |
| Purchase Of Investment | $-4,043,710,996 | $-3,951,786,619 | $-3,972,625,690 | $-3,184,308,511 |
| Net Business Purchase And Sale | $22,675,925 | $-10,443,459 | $-8,168,981 | $-134,519,779 |
| Sale Of Business | $22,675,925 | - | $0 | $0 |
| Purchase Of Business | $0 | $-10,443,459 | $-8,168,981 | $-134,519,779 |
| Net Intangibles Purchase And Sale | $-180,885 | $-76,309,953 | $-661,687 | $-11,154,160 |
| Purchase Of Intangibles | $-180,885 | $-76,309,953 | $-661,687 | $-11,154,160 |
| Net PPE Purchase And Sale | $-15,453,378 | $-19,508,694 | $-18,998,716 | $-31,100,478 |
| Sale Of PPE | $539,153 | $3,501 | $2,831,135 | $862,411 |
| Purchase Of PPE | $-15,992,531 | $-19,512,195 | $-21,829,851 | $-31,962,889 |
| Taxes Refund Paid | $-434,123 | $473,801 | $-9,534,368 | $-5,173,299 |
| Interest Received Cfo | $59,844,789 | $113,803,243 | $81,581,280 | $5,647,100 |
| Interest Paid Cfo | $-541,487 | $-804,061 | $-4,445,093 | $-14,544,287 |
| Change In Working Capital | $-1,022,952,489 | $-374,082,152 | $-808,069,775 | $-442,839,298 |
| Change In Other Working Capital | $-1,197,129,170 | $-298,177,146 | $-771,457,569 | $-447,681,170 |
| Change In Other Current Liabilities | $39,459,680 | $-66,550,355 | $37,130,353 | $-35,298,167 |
| Change In Inventory | $33,669,039 | $26,886,451 | $-28,096,627 | $-40,364,103 |
| Change In Receivables | $101,047,962 | $-36,241,101 | $-45,645,932 | $80,504,142 |
| Other Non Cash Items | $-117,678,841 | $-137,462,946 | $-107,035,825 | $1,200,840 |
| Stock Based Compensation | $28,006,768 | $23,206,908 | $66,189,753 | $103,286,263 |
| Unrealized Gain Loss On Investment Securities | $59,208,775 | $-58,331,193 | $-26,024,040 | $-8,086,124 |
| Asset Impairment Charge | $254,952,733 | $11,253,355 | $0 | $0 |
| Deferred Tax | $-21,166,997 | $-1,989,730 | $13,641,031 | $3,318,940 |
| Deferred Income Tax | $-21,166,997 | $-1,989,730 | $13,641,031 | $3,318,940 |
| Depreciation Amortization Depletion | $65,205,974 | $53,097,210 | $50,930,096 | $76,515,345 |
| Depreciation And Amortization | $65,205,974 | $53,097,210 | $50,930,096 | $76,515,345 |
| Depreciation | $65,205,974 | $53,097,210 | $50,930,096 | $76,515,345 |
| Pension And Employee Benefit Expense | $-2,744,778 | $-611,507 | $12,837 | $158,712 |
| Gain Loss On Investment Securities | $-26,543,354 | $-4,668 | $-21,006 | $-217,061 |
| Net Foreign Currency Exchange Gain Loss | $51,156,494 | $-27,842,222 | $23,232,582 | $-48,978,877 |
| Gain Loss On Sale Of PPE | $31,509 | $9,336 | $-1,273,194 | $-26,841 |
| Gain Loss On Sale Of Business | $-1,266,192 | $-60,638,347 | $0 | $0 |
| Net Income From Continuing Operations | $374,470,762 | $86,453,494 | $247,049,827 | $-254,394,908 |
| Other Cash Adjustment Outside Changein Cash | - | - | - | - |
| Proceeds From Stock Option Exercised | - | - | - | - |
Fetched: 2026-04-30